OBJECTIVE: This study investigated the potential synergistic effects of two inducers of apoptosis: the small molecule ABT-737 and arsenic trioxide (ATO). METHODS: Human gastric carcinoma cell lines SGC-7901 and MGC-803 were used to determine the effects of ABT-737 and ATO (alone or in combination) on cell proliferation and apoptosis in vitro. In vivo effects of these drugs were investigated in SGC-7901 solid tumours, grown in immunodeficient mice. RESULTS: ABT-737 and ATO inhibited proliferation and induced apoptosis in SGC-7901 and MGC-803 cells in concentration- and time-dependent manners, and showed a synergistic effect. ABT-737 disturbed the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large; ATO downregulated myeloid cell leukaemia (Mcl)-1 protein and upregulated Mcl-1short, the short splicing variant. ABT-737 and ATO significantly suppressed SGC-7901 xenograft growth, synergistically inhibited tumour growth and induced apoptosis in vivo. CONCLUSIONS: This study provides preclinical evidence that ABT-737 and ATO synergize to induce apoptosis of gastric carcinoma cells, suggesting that further investigation of these agents (as potential treatments for gastric cancer) is warranted.
KangMHReynoldsCP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res2009; 15: 1126–1132.
5.
OltersdorfTElmoreSWShoemakerAR: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature2005; 435: 677–681.
6.
TahirSKYangXAndersonMG: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res2007; 67: 1176–1183.
7.
ShoemakerAROleksijewABauchJ: A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res2006; 66: 8731–8739.
8.
KonoplevaMContractorRTsaoT: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell2006; 10: 375–388.
9.
ChauhanDVelankarMBrahmandamM: A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene2007; 26: 2374–2380.
10.
Del Gaizo MooreVBrownJRCertoM: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest2007; 117: 112–121.
11.
KangMHKangYHSzymanskaB: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood2007; 110: 2057–2066.
12.
van DelftMFWeiAHMasonKD: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell2006; 10: 389–399.
13.
VoglerMWeberKDinsdaleD: Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ2009; 16: 1030–1039.
14.
WacheckVCejkaDSieghartW: Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther2006; 5: 1348–1354.
15.
TsujitaniSSaitoHWakatsukiT: Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today2012; 42: 225–232.
16.
LinXMorgan-LappeSHuangX: ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene2007; 26: 3972–3979.
17.
YeciesDCarlsonNEDengJ: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood2010; 115: 3304–3313.
18.
KeulingAMFeltonKEParkerAA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One2009; 4: e6651.
19.
TagschererKEFasslACamposB: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene2008; 27: 6646–6656.
20.
ChenSDaiYHaradaH: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res2007; 67: 782–791.
21.
OkumuraKHuangSSinicropeFA: Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-XL inhibitor, ABT-737. Clin Cancer Res2008; 14: 8132–8142.
EmadiAGoreSD: Arsenic trioxide—an old drug rediscovered. Blood Rev2010; 24: 191–199.
25.
ZhengYZhouMYeA: The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol2010; 8: 31.
26.
LiYQuXQuJ: Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett2009; 284: 208–215.
27.
MoralesAAGutmanDLeeKP: BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood2008; 111: 5152–5162.
28.
ChenHSunBPanS: Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs2009; 20: 131–140.
29.
ChouTC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev2006; 58: 621–681.
30.
HanahanDWeinbergRA: Hallmarks of cancer: the next generation. Cell2011; 144: 646–674.
31.
LesseneGCzabotarPEColmanPM: BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov2008; 7: 989–1000.
32.
WillisSNChenLDewsonG: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-XL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev2005; 19: 1294–1305.
KutukOLetaiA: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res2008; 68: 7985–7994.
35.
SieghartWLosertDStrommerS: Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol2006; 44: 151–157.
36.
BaeJLeoCPHsuSY: MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem2000; 275: 25255–25261.
37.
LuoLQiaoHMengF: Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int J Cancer2006; 118: 1823–1830.
38.
BaumgartnerMSturlanSRothE: Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer2004; 112: 707–712.
39.
ZhangTCCaoEHLiJF: Induction of apoptosis and inhibition of human gastric cancer MCG-803 cell growth by arsenic trioxide. Eur J Cancer1999; 35: 1258–1263.
